Open To Accrual A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid TumorsProtocol NumberOSU-23427Learn more
Open To Accrual A Study of V940 Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Non-small Cell Lung Cancer (V940-002)Protocol NumberOSU-23367Learn more
Open To Accrual OSU-24210: SAR443579 Comb Aza + Venet Adlt CD123 ND-AML Ineligible Intensive Chemo - Substudy 01Protocol NumberOSU-24210Learn more
Open To Accrual A Study of DR-01 in Subjects With Large Granular Lymphocytic Leukemia or Cytotoxic LymphomasProtocol NumberOSU-22311Learn more
Open To Accrual OSU-24220: ZE46-0134 Adlts FLT3 mutated Relapsed or Refractory Acute Myeloid Leukemia (AML)Protocol NumberOSU-24220Learn more
Open To Accrual OSU-24190: JCAR017 Subjects Relapsed or Refractory CLL or Small Lymphocytic LymphomaProtocol NumberOSU-24190Learn more
Open To Accrual A Phase 2 Study of Firi-cel in Patients With Relapsed/Refractory Large B-cell LymphomaProtocol NumberOSU-23331Learn more
Open To Accrual A Study of DSP-5336 in Relapsed/Refractory AML/ ALL With or Without MLL Rearrangement or NPM1 MutationProtocol NumberOSU-23161Learn more
Open To Accrual ONC-392 Versus Docetaxel in Metastatic NSCLC That Progressed on PD-1/PD-L1 InhibitorsProtocol NumberOSU-23087Learn more
Open To Accrual COMbination Regimens in MM Post AHCT to elimiNate MRD Utilizing IbERdomideProtocol NumberOSU-23153Learn more
